NCT02564211View on ClinicalTrials.gov

Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849)

PHASE3CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

October 26, 2015

Primary Completion Date

March 7, 2017

Study Completion Date

March 7, 2017

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

Ipragliflozin

one 50 mg tablet QD

DRUG

Sitagliptin

one 50 mg tablet QD

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT02564211 - Ipragliflozin Add-on Long-term Study in Japanese Participants With Type 2 Diabetes Mellitus on Sitagliptin (MK-0431J-849) | Biotech Hunter | Biotech Hunter